Global /Australia /Healthcare /Drug Manufacturers - General /ANR
chevron_leftBack
Anatara Lifesciences Ltd. logo

Anatara Lifesciences Ltd.

ANR
ASX: ANR Delayed
0.0090AUD 0%
0.0063 USD
As of 10 June 2026, Anatara Lifesciences Ltd. has a market cap of $2.0M USD, ranking #47172 globally and #1747 in Australia. It ranks #4179 in the Healthcare sector, and #1322 in the Drug Manufacturers - General industry.
Global Rank
47172
Country Rank
1747
Sector Rank
4179
Industry Rank
1322
Key Stats
Market Cap
$2.0MUSD
2.84M AUD
Enterprise Value
$1.24MUSD
1.76M AUD
Revenue (TTM)
$439.43KUSD
623.76K AUD
EBITDA (TTM)
-$918.4KUSD
-1.3M AUD
Net Income (TTM)
-$921.9KUSD
-1.31M AUD
EBITDA Margin
-209%
Profit Margin
-210%
PS Ratio
4.6
PB Ratio
2.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
David Brookes open_in_new
Founded
2010
Website
anataralifesciences.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
0% -10% 11% -36% -36% 64%

News

Loading...

Markets

Exchange Ticker Price
Australian Securities Exchange
MIC: XASX
PRIMARY
ANR
Anatara Lifesciences Ltd
ISIN: AU000000ANR0
Shares Out.:
315.951M1 Shares Float: 313.224M2
TV:
SA:
YF:
GF:
BA:
ANR
MS:
0.0090 AUD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Anatara Lifesciences Ltd.

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company’s products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and Detach for the treatment of diarrhea in piglets. It also develops anti-obesity project, an oral medication to assist weight reduction and control. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.

Similar Companies

Industry: Drug Manufacturers - General (Australia)
Name
Market Cap diff.
PE
$22.53B
31.98B AUD
1M%
52.3
$914.36M
1.3B AUD
46K%
-
$341.81M
485.18M AUD
17K%
-
$331.1M
469.99M AUD
16K%
14.5
$213.62M
303.23M AUD
11K%
-
$164.27M
233.18M AUD
8K%
-
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
38M%
38.1
JNJ
$547.28B
27M%
26.4
ABBV
$360.63B
18M%
97.4
$321.17B
256.25B CHF
16M%
19.9
AZN
$287.57B
215.59B GBP
14M%
27.6
NOVN
$274.35B
218.9B CHF
14M%
20.5
chevron_leftBack